klyx 1 + 250 mg/ml rektalvæske, opløsning
ferring lægemidler a/s - docusatnatrium, sorbitol - rektalvæske, opløsning - 1 + 250 mg/ml
klyx 1 + 250 mg/ml rektalvæske, opløsning
orifarm a/s - docusatnatrium, sorbitol - rektalvæske, opløsning - 1 + 250 mg/ml
klyx 1 + 250 mg/ml rektalvæske, opløsning
2care4 aps - docusatnatrium, sorbitol - rektalvæske, opløsning - 1 + 250 mg/ml
epaclob 1 mg/ml oral suspension
ethypharm - clobazam, sorbitoloplØsning 70% - oral suspension - 1 mg/ml
klyx 1 + 250 mg/ml rektalvæske, opløsning
abacus medicine a/s - docusatnatrium, sorbitol - rektalvæske, opløsning - 1 + 250 mg/ml
xtandi
astellas pharma europe b.v. - enzalutamide - prostatiske neoplasmer - endokrine terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
navelbine 20 mg kapsler, bløde
pierre fabre pharma norden ab - vinorelbintartrat - kapsler, bløde - 20 mg
navelbine 30 mg kapsler, bløde
pierre fabre pharma norden ab - vinorelbintartrat - kapsler, bløde - 30 mg
navelbine 80 mg kapsler, bløde
pierre fabre pharma norden ab - vinorelbintartrat - kapsler, bløde - 80 mg
epaclob 2 mg/ml oral suspension
ethypharm - clobazam, sorbitoloplØsning 70% - oral suspension - 2 mg/ml